Breakdown | |||||
TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
149.25B | 155.63B | 134.43B | 159.46B | 142.20B | 106.72B | Gross Profit |
43.10B | 44.16B | 38.04B | 46.40B | 40.89B | 28.77B | EBIT |
17.28B | 19.02B | 13.11B | 21.17B | 17.88B | 7.70B | EBITDA |
24.24B | 26.73B | 20.31B | 28.37B | 23.79B | 13.21B | Net Income Common Stockholders |
11.44B | 13.52B | 8.34B | 14.79B | 12.57B | 5.27B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
29.40B | 35.33B | 28.30B | 28.57B | 34.53B | 36.38B | Total Assets |
214.31B | 210.87B | 208.28B | 185.63B | 172.51B | 152.73B | Total Debt |
35.38B | 35.80B | 37.53B | 18.63B | 17.89B | 20.41B | Net Debt |
5.98B | 468.00M | 9.79B | -9.94B | -16.63B | -15.96B | Total Liabilities |
79.80B | 74.34B | 79.19B | 65.90B | 62.94B | 55.11B | Stockholders Equity |
134.51B | 136.52B | 129.10B | 119.73B | 109.57B | 97.50B |
Cash Flow | Free Cash Flow | ||||
0.00 | 13.47B | -12.99B | -702.00M | 4.12B | 14.56B | Operating Cash Flow |
0.00 | 19.17B | 7.60B | 11.05B | 12.35B | 17.52B | Investing Cash Flow |
0.00 | -6.06B | -20.23B | -12.79B | -8.54B | -2.79B | Financing Cash Flow |
0.00 | -6.18B | 13.05B | -5.74B | -6.26B | 2.42B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | ¥159.83B | 11.52 | 3.52% | 15.78% | 62.07% | ||
77 Outperform | $230.51B | 19.98 | 4.82% | 3.35% | -6.42% | -15.92% | |
76 Outperform | €222.99B | 12.06 | 14.03% | 2.56% | 4.59% | 64.99% | |
76 Outperform | ¥145.61B | 12.49 | 2.58% | 20.05% | -26.75% | ||
75 Outperform | ¥191.22B | 8.57 | 8.48% | 5.16% | 4.64% | 24.27% | |
74 Outperform | ¥239.32B | 19.80 | 1.12% | 16.07% | 61.09% | ||
66 Neutral | $4.51B | 12.22 | 5.40% | 3.63% | 4.14% | -12.01% |
CKD Corporation announced corrections to its Consolidated Financial Results for the fiscal year ended March 31, 2025. The revisions, which include updated numerical data, are intended to provide more accurate financial information. These corrections could impact stakeholders’ understanding of the company’s financial health and operational efficiency.
The most recent analyst rating on (JP:6407) stock is a Buy with a Yen3400.00 price target. To see the full list of analyst forecasts on CKD Corporation stock, see the JP:6407 Stock Forecast page.
CKD Corporation announced executive personnel changes, effective May 13, 2025. Akihiro Ueno has been appointed as Executive Officer while retaining his role as President of CKD Korea Corporation. Akihiro Ito has been promoted to Fellow and General Manager of the New Business Development Office. Additionally, Seiichi Hamguchi will retire from his position as Executive Officer and transition to a Special Advisor role. These changes are part of CKD’s strategic efforts to strengthen leadership and drive new business initiatives.
The most recent analyst rating on (JP:6407) stock is a Buy with a Yen3400.00 price target. To see the full list of analyst forecasts on CKD Corporation stock, see the JP:6407 Stock Forecast page.
CKD Corporation announced an increase in its year-end dividend to 42 yen per share, up from the previous forecast of 41 yen, resulting in a total annual dividend of 80 yen per share. This decision reflects the company’s commitment to shareholder returns while maintaining a target dividend payout ratio of 40% and supporting business expansion through strategic investments.
The most recent analyst rating on (JP:6407) stock is a Buy with a Yen3400.00 price target. To see the full list of analyst forecasts on CKD Corporation stock, see the JP:6407 Stock Forecast page.